Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2021 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Present at the H.C. Wainwright Global Investment Conference

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics...
September 02, 2021 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug

RadioMedix, Inc. is a key manufacturer and supplier of cGMP radiotherapeutics for late-stage clinical trials and commercial production RadioMedix will produce cGMP drug product for Rhenium-186...
August 21, 2021 09:24 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer

Data shows that the administration of Rhenium-186 NanoLiposome (186RNL) via convection enhanced delivery for recurrent glioblastoma is well tolerated at significantly higher doses of radiotherapy than...
August 19, 2021 07:00 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial

Positive data to support FDA IND application for the clinical evaluation of Rhenium-186 Nanoliposome (186RNL) targeted radiotherapy for patients with leptomeningeal metastases (LM) Presentation...
August 13, 2021 07:51 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Present Data from ReSPECT™-GBM Trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting

AUSTIN, Texas, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare...
August 11, 2021 10:12 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome

AUSTIN, Texas, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare...
August 05, 2021 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
July 27, 2021 07:00 ET | Source: Plus Therapeutics Inc.

Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement

Global agreement covers 186RNL manufacturing intermediate Manufacturer ABX Advanced Biochemical Compounds GmbH is key worldwide supplier of radiopharmaceutical products and services AUSTIN, Texas,...
July 22, 2021 16:05 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

AUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
July 22, 2021 07:00 ET | Source: Plus Therapeutics Inc.

Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT™-GBM Trial

Recurrent Glioblastoma Trial Update Planned for Q4 2021 AUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical...